

AWARD NUMBER: W81XWH-16-1-0374

TITLE: Control of Atherosclerosis Regression by PRMT2 in Diabetes

PRINCIPAL INVESTIGATOR: Edward A. Fisher

CONTRACTING ORGANIZATION: New York University Grossman School of Medicine

REPORT DATE: APRIL 2021

TYPE OF REPORT: FINAL

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> APRIL 2021		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED</b> 1AUG2016 - 31DEC2020	
<b>4. TITLE AND SUBTITLE</b>  Control of Atherosclerosis Regression by PRMT2 in Diabetes				<b>5a. CONTRACT NUMBER</b> W81XWH-16-1-0374	
				<b>5b. GRANT NUMBER</b> PR150743P1	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Edward A. Fisher  E-Mail: Edward.Fisher@nyulangone.org				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  New York University School of Medicine 550 First Avenue New York, NY 10016-6402				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Macrophages play key roles in progression of atherosclerosis. Our goal is to understand the mechanisms by which atherosclerosis can be clinically regressed by altering the macrophage state in the plaques to resolve the inflammation, as well as to develop new therapeutic strategies to promote atherosclerosis regression by altering the macrophage activation state. We have found that successful atherosclerosis regression requires the alteration of macrophages in the plaques to a tissue repair "alternatively" activated state. This switch in activation state requires the action of TH2 cytokines interleukin (IL)-4 or IL-13. To accomplish our goals, we are testing if these molecules, or derivative of these molecules, will be able to accelerate atherosclerosis regression in mouse models. Additionally, we will develop nanomedicines that can favorably and rapidly affect the content and inflammatory state of macrophages in atherosclerotic plaques to promote regression. Concurrently, we will characterize the macrophages to understand the mechanisms that promote atherosclerosis regression.					
<b>15. SUBJECT TERMS</b>  NONE LISTED					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  Unclassified	<b>18. NUMBER OF PAGES</b>  13	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified			<b>19b. TELEPHONE NUMBER (include area code)</b>

<b>TABLE OF CONTENTS:</b>	page number
1. Introduction.....	2
2. Keywords... ..	2
3. Accomplishments.....	2-8
4. Impact.....	8
5. Changes/Problems.....	8
6. Products.....	8
7. Participants & Other Collaborating Organizations.....	8-9
8. Special Reporting Requirements.....	10
9. Appendices.....	10
References.....	11

## 1. INTRODUCTION:

High plasma cholesterol and diabetes are major risk factors for atherosclerosis. People with diabetes are 2-4 times more likely to suffer from coronary heart disease (CHD). Given that 1 in 4 veterans who receive care from VA hospitals has diabetes testifies to the importance of this problem for military personnel. In human diabetics, treatment with cholesterol-lowering drugs such as statins fails to fully reduce the risk for atherosclerosis. Understanding the factors that are altered as a result of impaired glucose homeostasis is a significant area of cardiovascular research that has important ramifications for the health and well-being of the military workforce. Established coronary lesions of adulthood begin in childhood. Over time macrophages accumulate cholesterol, which promotes their differentiation into foam cells that become trapped in the artery, contributing to the growth of atherosclerotic plaques. Owing to a diminished capacity of cholesterol-engorged macrophages to migrate, they accumulate and fail to resolve inflammation, which leads to the plaque becoming unstable and rupturing, resulting in heart attacks and stroke. Accordingly, an important clinical goal to reduce CHD risk is to promote the regression of atherosclerosis by eliciting macrophage cholesterol efflux and macrophage migration from plaques.

Work from our labs has shown that regression of atherosclerosis is mediated in part by the Liver X Receptor (LXR) family of nuclear receptors through the induction of genes involved in cholesterol efflux. Given that we also found that regression of atherosclerosis is impaired in the context of diabetes, we proposed that changes in glucose levels modulate LXR-dependent gene expression and reduce the expression of LXR target genes like the cholesterol transporter protein *ABCA1*, and that this molecular mechanism might account for the increased rate of atherosclerosis in diabetics. We showed that LXR-mediated *ABCA1* expression and ABCA1-dependent cholesterol efflux is compromised in macrophages exposed to high, compared to normal, levels of blood glucose. Moreover, we identified the protein arginine methyltransferase 2 (PRMT2), cellular levels of which are reduced in high versus normal glucose, as a factor that mediates this effect. Macrophages devoid of PRMT2 showed reduced LXR-dependent induction of *ABCA1* and reduced ABCA1-mediated cholesterol efflux, thus mimicking the effect of high glucose. Expression of *PRMT2* was lower in monocytes from diabetic mice. Our studies revealed PRMT2 as a glucose-sensitive factor that plays a role in the induction of *ABCA1* by LXR and affects cholesterol efflux. Thus, PRMT2 might be critical in mediating the increased incidence of atherosclerosis in diabetics. The goal of this proposal is to understand how PRMT2 deficiency promotes atherosclerosis during diabetes.

2. **KEYWORDS:** PRMT2, atherosclerosis regression, diabetes, macrophages, asymmetric dimethyl arginine, regulation of gene expression

## 3. ACCOMPLISHMENTS:

- What were the major goals and objectives of the project?

### The major goals of the project are:

- 1) determine the role PRMT2 plays in the impaired regression of atherosclerosis in diabetes
- 2) determine the substrates of PRMT2 in macrophages in normal and high glucose
- 3) determine the molecular regulation of PRMT2

- What was accomplished under these goals? Major activities for this reporting period:

### Specific Aim 1: To determine the role PRMT2 plays in the impaired regression of atherosclerosis in diabetes


#### Major Task 1: Bone Marrow transplant from *PMRT2*<sup>-/-</sup> into *LDLR*<sup>-/-</sup> mice (completed)

Subtask 1: Generate *PMRT2*<sup>-/-</sup> and WT mice for bone marrow transplant into *LDLR*<sup>-/-</sup> mice

Subtask 2: Perform bone marrow transplants of *PMRT2*<sup>-/-</sup> into *LDLR*<sup>-/-</sup> mice and enter mice into study protocols

We have established a colony of *PRMT2*<sup>-/-</sup> mice to determine how *PRMT2* affects atherosclerosis regression in diabetes. We used these mice to perform bone marrow transplants into atherosclerosis-prone *LDLR*<sup>-/-</sup> mice and examined the effect on atherosclerosis regression with and without diabetes. We used a bone marrow transplant approach from wild type (WT) and *PRMT2*<sup>-/-</sup> mice, since this has the potential to uncover the importance of *PRMT2* activities within myeloid-derived immune cells, while avoiding confounding effects of *PRMT2* expression in other organs. This was crucial given that mice with a whole body knock out *PRMT2*, while viable and fertile, were defective in leptin signaling by virtue of *PRMT2*'s effect on *STAT3* methylation and signaling in the hypothalamus (1).

The bone marrow transplant/atherosclerosis regression studies were performed using the following scheme (Fig.1). After bone marrow transplant, mice were allowed to recover for 4 weeks, then placed on a high fat, high cholesterol “western diet” for 20 weeks to promote the formation of advanced atherosclerotic plaques. At 19 weeks, half the mice were made diabetic using STZ, and the other half were not, and injected with citrate buffer as a control. To induce regression, mice were treated with an anti-sense oligonucleotide (ASO) against the *APOB* gene to reduce LDL cholesterol levels and promote regression. Mice were placed on chow diet for 3 weeks, plaques harvested and plaque area measured.




**Figure 1. Experimental design for the regression of atherosclerosis studies.** *LDLR*<sup>-/-</sup> mice were irradiated to kill the endogenous bone marrow cells, and bone marrow transplants into them were performed from *PRMT2*<sup>-/-</sup> or littermate wild type controls. Mice were allowed to recover for 4 weeks and placed on a western diet for 20 weeks. A group of animals was sacrificed after 20 weeks of western diet feeding and used as the baseline group. Two other groups of animals received citrate buffer or STZ to induce diabetes at 19 weeks. At 20 weeks, to lower LDL cholesterol, regression and regression/STZ groups received *APOB* anti-sense oligonucleotide (ASO) and were switched to a chow diet. Animals were sacrificed 3 weeks later and the indicated parameters analyzed.

**Major Task 2:** Analysis of aortic arches from regression cohort +/- *PMRT2*, +/- diabetes


Subtask 1: Sac mice, collect serum, harvest, fix and embed aortic tissues

The *PRMT2*<sup>-/-</sup> bone marrow recipients had similar body weight, cholesterol and glucose levels compared to their WT bone marrow recipient counterparts (Fig. 2A-C; see 19 week columns). As expected, the glucose levels were dramatically higher in STZ-treated mice than in control mice (Fig. 2C; see green and black bars, Reg 3 weeks). Similar reductions in cholesterol were observed in normal and diabetic mice upon reversal of hyperlipidemia (Fig. 2B; see Reg 3 weeks).



**Figure 2. Parameters of the *PMRT2*<sup>-/-</sup> and WT bone marrow transplant mice.** Mice weights, total cholesterol and blood glucose levels were determined in wild type and *PMRT2*<sup>-/-</sup> cohorts. Base= baseline; ND= non-diabetic; D= diabetic; WT= wild type; PKO= *PMRT2* knock out (*PMRT2*<sup>-/-</sup> bone marrow). The bars above “19 weeks” are the measurements taken after 19 weeks on western diet (progression phase). The bars above the “Reg 3 weeks” are measurements taken at the end of the 3-week regression period.


To determine the effect of *PRMT2* on atherosclerosis regression, we measured plaque area and total macrophage content by quantifying the percent of the macrophage marker CD68 (Fig. 3A). We have reported that hyperglycemia impaired atherosclerosis regression (2). The preliminary



**Figure 3. *PRMT2* deficiency (PKO) increases plaque macrophage content and macrophage retention in normoglycemic but not diabetic mice.** A) Aortic root sections from baseline and regression groups were stained for CD68 to measure total macrophage content. The percent area occupied by CD68+ cells was quantified using Image Pro Plus Software. B) More Edu-labeled macrophages are retained in the regression plaque in PKO mice under normoglycemic than in diabetic conditions. Data (mean ± SEM) (n≥8) were analyzed using one-way ANOVA followed by Tukey’s multiple comparison test. P<0.05 values were considered significant, \*P<0.05, \*\*P<0.005, and \*\*\*P<0.0005.

results show the following: *Prmt2*<sup>-/-</sup> baseline mice had higher macrophage contents in their plaques compared to WT mice. After 3 weeks of reduction in plasma cholesterol levels, we observed reduced macrophage content in the normoglycemic mice expressing WT and *Prmt2*<sup>-/-</sup> indicative of atherosclerosis regression. As expected, regression in WT mice under diabetic conditions mice was impaired. By

contrast, *Prmt2*<sup>-/-</sup> mice did not alter plaque macrophage content under diabetic versus non-diabetic conditions: in other words, regression was independent of diabetes in *Prmt2*<sup>-/-</sup> mice (Fig. 3A). This is consistent with *PRMT2* expression being low under hyperglycemia. Since plaque macrophage content reflects multiple kinetic factors including monocyte recruitment, macrophage proliferation and apoptosis, we also measured each of these parameters. While we found no difference in macrophage proliferation and apoptosis, we did find a significant decrease in the recruitment of inflammation-prone Ly6Chigh monocytes into the plaques of *Prmt2*<sup>-/-</sup> mice relative to WT mice under diabetes ( Fig 3B). These findings indicate that *Prmt2*<sup>-/-</sup> mice have reduced leukocyte recruitment upon inflammation and diabetes. For all of the mice, RNA samples have been isolated from plaque macrophages using laser capture microdissection and submitted for RNA-seq to infer the factors and pathways regulated by *PRMT2* based on bioinformatic analysis.




**Figure 4. PRMT2 is localized to the nucleus in BMDMs, and histone H3 arginine 8 is a PRMT2 substrate.** A) BMDMs cultured under normal glucose were subjected to immunofluorescence with an antibody against PRMT2 (pink). Nuclei were stained with DAPI (blue). Inset: enlargement of a cell expressing PRMT2. Scale bar 50 microns. No signal above background was observed in BMDMs from *Prmt2*<sup>-/-</sup> mice (not shown). B) Extracts from BMDMs from wild-type (WT) and *Prmt2*<sup>-/-</sup> mice cultured under normal glucose were immunoblotted with an antibody specific for histone H3 asymmetric dimethyl arginine 8 (H3K8Me2a) and for total histone H3 (H3 Total).

**Specific Aim 2:** To determine the substrates of PRMT2 in macrophages in normal and high glucose that affects LXR transcriptional activity.

**Major Task 1:** Conduct studies to assess the PRMT2 substrate capture by immunoprecipitation (IP) using asymmetric arginine dimethylation antibody.

We have advanced the potential mechanism for PRMT2's effects. We have showed that PRMT2 in BMDMs is localized to the nucleus and identified histone H3 arginine 8 asymmetric dimethylation (H3R8Me2a) as a substrate for PRMT2 (Fig 4), since this histone modification in BMDMs lacking PRMT2 is no longer observed.




**Figure 5. PRMT2 and H3R8me2a occupancy of *Abca1* promoter at LXR binding in normoglycemic and hyperglycemic conditions.** A) Schematic of the mouse *ABCA1* genomic locus. Rectangles represent exons, and the arrow denotes the transcription start site. The pair of red arrows above the gene show the location of the primers used: promoter, corresponding to LXR binding site, and intron, used as a negative control. B-C) Chromatin was immunoprecipitated from BMDMs cultured in normoglycemic and hyperglycemic conditions using an antibody specific for PRMT2 (Atlas Antibodies Cat# HPA029591) or H3R8me2a (Diagenode Inc C15410286), and amplified using primers encompassing the promoter, where LXR binding, or the intron, where it does not bind. Isotype-matched IgG was used as a control. Percent of precipitated DNA compared to total input DNA is shown. Data represent an average of three experiments. Error bars represent SEM. \*P<0.05

This is consistent with PRMT2's previously reported *in vitro* H3R8me2a methylation activity using either peptides or recombinant histones as substrates (3). It has also been shown by ChIP-seq in cell culture models of glioblastoma that H3R8Me2a is important for the maintenance of active promoters and enhancers (4). The H3R8Me2a modification has also been reported to promote an association with Tudor-domain containing proteins such as Spindlin-1 to regulate gene transcription (5). Tudor domain proteins function as molecular adaptors, binding methylated arginine on substrates to promote the assembly of macromolecular complexes including those involved in chromatin modifications.

To further connect PRMT2 to LXR-dependent regulation of *Abca1*, we performed a chromatin immunoprecipitation (ChIP) assay to determine: 1) whether PRMT2 occupies the *Abca1* promoter where LXR has been

shown to bind; 2) whether this is associated with H3R8Me2a occupancy; and 3) whether both PRMT2 and H3R8Me2a are reduced in cells cultured under hyperglycemic conditions where PRMT2 levels are low. We found that PRMT2 and H3R8Me2a in BMDMs cultured under normal




**Figure 6. PRMT2 substrates and functional classes.** WT and *PRMT2*<sup>-/-</sup> BMDMs were lysed and proteins were affinity purified with an asymmetric arginine dimethylation antibody and proteins identified by mass spectrometry. GO classes for the substrates enriched in WT but absent in *PRMT2*<sup>-/-</sup> are shown.

substrates in an unbiased manner by proteomic analyses of macrophages cultured under normal glucose concentrations from WT and *Prmt2*<sup>-/-</sup> BMDMs (Fig. 6). We used affinity purification with an antibody specific to asymmetric arginine dimethylation to identify PRMT2 substrates. We were able to see an enrichment of 120 asymmetric arginine dimethylated proteins in the immunoprecipitated fraction of the WT compared to *Prmt2*<sup>-/-</sup> BMDMs. We interpret these as direct PRMT2 substrates. Surprisingly, we also found 80 arginine dimethylated proteins present in the *Prmt2*<sup>-/-</sup> BMDMs that were not present in WT BMDMs. We interpret this as PRMT2 negatively regulating another asymmetric arginine dimethylation enzyme. We also identified a set of proteins (268) that were present in both WT and *Prmt2*<sup>-/-</sup> BMDMs and interpret these as substrates modified by an arginine dimethylation enzyme other than PRMT2. We are focusing our efforts on characterizing the direct PRMT2 substrates. Pathway analysis using Metascape showed that proteins enriched in WT but absent in *Prmt2*<sup>-/-</sup> BMDMs were associated with GO classes that include nucleotide metabolic processes. We will validate the top asymmetric arginine demethylated substrates identified by mass spectrometry, and once validated we will test their functional significance.


**Major Task 2:** Mapping PRMT2 cis regulatory elements by reporter gene assays based on ENCODE data  
**Subtask 1:** Test PRMT2 promoter luciferase construct for glucose regulated expression.

glucose occupy the *Abca1* promoter above the IgG non-specific antibody control (Fig 5A-B; blue bars). Moreover, reduced occupancy of both PRMT2 and H3R8Me2a occurred in BMDMs cultured in high glucose, which have reduced PRMT2 levels (Fig 5B, red bars compared to blue bars). This is specific since a downstream intronic region on *Abca1* showed no recruitment above the IgG control under either normoglycemia or hyperglycemic conditions (Fig 5C). This is consistent with a reduction in PRMT2 expression under hyperglycemic conditions, and H3R8Me2a being PRMT2 substrate.

We have also characterized PRMT2



**Figure 7. Reduction of steady state PRMT2 mRNA and protein in high glucose.** A) RAW, B) BMDMs, C), THP1 cells were cultured in normal glucose (NG) and high glucose (HG) for 1 week, and PRMT2 expression levels were measured by qPCR and normalized to cyclophilin. Protein extract were prepared and blotted for PMRT2, and beta-actin as a loading control.



**Figure 8. Post transcriptional regulation of PRMT2 mRNA.** A) Steady state and nascent RNA of PRMT2 was measured by qPCR from BMDMs cultured in normal glucose (NG) and high glucose (HG). Whereas the PRMT2 steady state mRNA level is reduced in cells cultured in high glucose compared to normal glucose, the nascent RNA is not. This is true for two independent primer sets that measures nascent PRMT2 RNA. This indicates that the reduction of PRMT2 mRNA is not at the level of transcription initiation. B) PRMT2-3' UTR-luciferase reporter construct was transfected into 293 cells in normal and high glucose and activity measured and presented as relative luciferase units (RLU). Note the reduction in luciferase reporter activity in high glucose, suggesting that the decrease in PRMT2 mRNA is via the 3' UTR.

sufficient to confer glucose regulation on PRMT2 expression (shown in the previous progress report).

Given that the glucose-dependent regulation of PRMT2 appears to be post-transcriptional, we examined whether the PRMT2 mRNA 3'UTR was a potential target regulation. To do this, we used a luciferase reporter construct fused to the 3' UTR of PRMT2 compared to a reporter without the PRMT2 3' UTR. We found a reduction in expression of the luciferase reporter in high compared

We have shown that the steady state PRMT2 mRNA and protein levels are reduced in high as compared to low glucose in the murine macrophage RAW cell line, both in mouse BMDMs and in human macrophage cell line THP-1 (Fig. 7). However, we have recently found that PRMT2 nascent RNA, a surrogate for newly transcribed RNA and measured by using primer pairs that span an intron-exon junction, is not reduced when cells are cultured in high glucose (Fig. 8A). This suggests that the effect of glucose is not at the level of transcription initiation, but rather regulated post-transcriptionally. Consistent with this idea, the PRMT2 promoter linked to a luciferase reporter gene did not show a change in luciferase activity in cells cultured in low and high glucose. Thus, the PRMT2 promoter alone is not sufficient to confer glucose regulation on PRMT2 expression (shown in the previous progress report).

Subtask 1: Test PRMT2 promoter luciferase construct for glucose regulated expression.

We have shown that the steady state PRMT2 mRNA and protein levels are reduced in high as compared to low glucose in the murine macrophage RAW cell line, both in mouse BMDMs and in human macrophage cell line THP-1 (Fig. 7). However, we have recently found that PRMT2 nascent RNA, a surrogate for newly transcribed RNA and measured by using primer pairs that span an intron-exon junction, is not reduced when cells are cultured in high glucose (Fig. 8A). This suggests that the effect of glucose is not at the level of transcription initiation, but rather regulated post-transcriptionally. Consistent with this idea, the PRMT2 promoter linked to a luciferase reporter gene did not show a change in luciferase activity in cells cultured in low and high glucose. Thus, the PRMT2 promoter alone is not

to normal glucose for the PRMT2 3' UTR construct compared to control (Fig. 8B), suggesting that the high glucose-dependent decrease in PRMT2 mRNA is controlled via its 3' UTR.

- **What opportunities for training and professional development did the project provide?**

Nothing to Report.

- **How were the results disseminated to communities of interest?**

We will disseminate our findings through publications in peer reviewed journals, although at this point we have nothing to report.

- **What do you plan to do during the next reporting period to accomplish the goals and objectives?**

Our goals for the future are to complete the analyses of the *Prmt2*<sup>-/-</sup> mice under regression conditions as a function of diabetes, and examine changes in gene expression by RNA-seq from laser captured micro dissected CD68<sup>+</sup> macrophages, and write this study up for publication.

We will validate the top the asymmetrically dimethylated substrates identified by mass spectrometry, and once validated we will begin to test their functional significance.

We will also continue to elucidate the mechanism whereby expression of PRMT2 is controlled by high glucose, focusing on the post-transcriptional regulatory mechanisms.

#### **4. IMPACT:**

Our work has shown that PRMT2 plays a major role in atherosclerosis regression in diabetes. We also expect that our proteomic analyses of PRMT2 substrates, which represent the first of its kind, will be useful in elucidating the mechanism of PRMT2 function in macrophages, and in identify possible interventions and biomarkers. Finally, understanding the regulation of PRMT2 expression will enable us to develop ways to restore the normal level of PRMT2 in diabetes, and prevent the cells from contributing to plaque formation.

#### **What was the impact on technology transfer?**

None at this point

#### **What was the impact on society beyond science and technology?**

None at this point

#### **5. CHANGES/PROBLEMS:**

Nothing to Report

#### **6. PRODUCTS:**

Nothing to Report

#### **7: PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

PIs

Name: Michael Garabedian, PhD.

Project Role: PI.

Nearest person month worked: 3

Contribution to Project:

Dr. Garabedian helped design and analyze the experiments involving the identification of the PRMT2 substrates and determining the regulation of PRMT2 expression by high glucose.  
Funding Support: CDMRP/NIH

Name: Edward Fisher, MD, PhD

Project Role: Partner PI.

Nearest person month worked: 2

Contribution to Project:

Dr. Fisher helped design experiments involving the role of PRMT2 in the regression of atherosclerosis and diabetes.

Funding Support: CDMRP/NIH

Post-doctoral fellows

Prashanth Thevkar Nagesh, PhD

Project Role: Post doc

Nearest person month worked: 9

Contribution to Project:

Dr. Nagesh performed the experiments involving the PRMT2 substrates identification and the PRMT2 gene regulation studies.

Funding Support: CDMRP/NIH

Beyza Vurusaner Aktas, PhD

Project Role: Post doc

Nearest person month worked: 9

Contribution to Project:

Dr. Aktas performed the experiments involving the impact of the loss of PRMT2 expression in the regression of atherosclerosis in diabetes.

Funding Support: CDMRP/NIH

Carmen Hannemann

Project Role: Graduate Student

Nearest person month worked: 6

Contribution to Project:

Carmen worked on the immunostaining analysis of the aortic plaques.

Tarik Zahr

Project Role: Technician

Nearest person month worked: 12

Contribution to Project:

Tarik worked on the immunostaining analysis of the aortic plaques.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

**What other organizations were involved as partners?**

Nothing to Report

**8 SPECIAL REPORTING REQUIREMENTS: COLLABORATIVE AWARDS:** For collaborative awards, independent reports are required from BOTH the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

An independent report will be submitted by Dr. Garabedian, the Initiating PI.

**9 APPENDICES:** none

## REFERENCES

1. Iwasaki H, Kovacic JC, Olive M, Beers JK, Yoshimoto T, Crook MF, Tonelli LH, Nabel EG. Disruption of protein arginine N-methyltransferase 2 regulates leptin signaling and produces leanness in vivo through loss of STAT3 methylation. *Circulation research*. 2010;107(8):992-1001. doi: 10.1161/CIRCRESAHA.110.225326. PubMed PMID: 20798359; PMCID: PMC2997704.
2. Parathath S, Grauer L, Huang LS, Sanson M, Distel E, Goldberg IJ, Fisher EA. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. *Diabetes*. 2011;60(6):1759-69. Epub 2011/05/13. doi: 10.2337/db10-0778. PubMed PMID: 21562077; PMCID: 3114401.
3. Blythe SA, Cha SW, Tadjuidje E, Heasman J, Klein PS. beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8 methyltransferase, Prmt2. *Dev Cell*. 2010;19(2):220-31. doi: 10.1016/j.devcel.2010.07.007. PubMed PMID: 20708585; PMCID: PMC2923644.
4. Dong F, Li Q, Yang C, Huo D, Wang X, Ai C, Kong Y, Sun X, Wang W, Zhou Y, Liu X, Li W, Gao W, Liu W, Kang C, Wu X. PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. *Nat Commun*. 2018;9(1):4552. doi: 10.1038/s41467-018-06968-7. PubMed PMID: 30382083; PMCID: PMC6208368.
5. Su X, Zhu G, Ding X, Lee SY, Dou Y, Zhu B, Wu W, Li H. Molecular basis underlying histone H3 lysine-arginine methylation pattern readout by Spin/Ssty repeats of Spindlin1. *Genes & development*. 2014;28(6):622-36. doi: 10.1101/gad.233239.113. PubMed PMID: 24589551; PMCID: PMC3967050.